Zepbound (Tirzepatide) Nausea: Supplements With the Best Evidence

How common is nausea on Zepbound?

The Zepbound label pools two placebo-controlled weight-management trials, SURMOUNT-1 and SURMOUNT-2, with adults treated for up to 72 weeks: 958 on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [4]. Nausea was reported by 8% of placebo patients and by 25% on 5 mg, 29% on 10 mg and 28% on 15 mg [4]. The rate at 10 mg was slightly higher than at 15 mg, so the label's numbers do not climb steadily with dose.

Nausea is the first reaction the label lists among the common adverse reactions reported in at least 5% of treated patients, alongside diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and GERD [4]. Counting every gastrointestinal event, 56% of patients on each Zepbound dose reported at least one, against 30% on placebo [4]. Discontinuation for a GI reaction was 1.9% on 5 mg, 3.3% on 10 mg and 4.3% on 15 mg, against 0.5% on placebo [4]. Severe GI reactions were reported in 1.7%, 2.5% and 3.1% respectively, against 1% on placebo [4].

When does nausea occur during treatment?

The label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [4]. Escalation is structured: 2.5 mg once weekly for 4 weeks as a starting dose, which is not a maintenance dose, then 5 mg, with any further 2.5 mg increase separated by at least 4 weeks on the current dose [4].

The label also notes that tirzepatide delays gastric emptying, that this delay is largest after the first dose, and that it diminishes over time [4].

How do the supplements compare?

The ginger trials studied chemotherapy nausea, the vitamin B6 trials studied pregnancy nausea, and the peppermint oil trials studied IBS symptoms and abdominal pain [1][2][3][5]. None of them enrolled people taking tirzepatide. The records differ in size and in what they measured. Ginger has the largest nausea dataset, from a trial that randomized 744 adults receiving chemotherapy [1]. Vitamin B6 has two positive trials in pregnancy nausea [2][3]. Peppermint oil's evidence is in IBS symptoms and abdominal pain rather than nausea [5].

Ginger

Ginger has the largest randomized nausea dataset among these supplements.

The URCC CCOP trial randomized 744 adults receiving chemotherapy to placebo or ginger 0.5 g, 1.0 g or 1.5 g daily; 576 were included in the final analysis (91% female, mean age 53) [1]. Patients took the capsules twice daily for six days, starting three days before chemotherapy, and every patient also received a 5-HT3 antagonist antiemetic on day 1 [1]. All three ginger doses reduced the severity of acute nausea on day 1 compared with placebo (p=0.003), and the largest reductions were at 0.5 g (p=0.017) and 1.0 g (p=0.036), not at the highest dose [1].

A laboratory study offers a possible mechanism: in guinea pig tissue, 6-gingerol, 8-gingerol, 10-gingerol and 6-shogaol slightly depressed M3 receptor responses, and 10-gingerol and 6-shogaol also depressed 5-HT3 receptor responses; the authors concluded that a weak inhibitory effect at M3 and 5-HT3 receptors may underlie ginger's effect on nausea and vomiting [6]. That is animal tissue.

Vitamin B6

Vitamin B6 has two randomized trials behind it, both in pregnancy nausea.

In a double-blind trial of 59 women, pyridoxine 25 mg orally every 8 hours for 72 hours reduced nausea scores by a mean 4.3 points in women whose baseline nausea was severe, against 1.8 points with placebo (P<0.01) [2]. In women with mild to moderate nausea, and in the group as a whole, the difference was not significant [2]. After three days, 8 of 31 women on B6 were still vomiting, against 15 of 28 on placebo (P<0.05) [2].

The larger trial randomized 342 women to pyridoxine 30 mg daily or placebo for five days and found a significantly greater fall in nausea scores with B6 (p=0.0008); the reduction in vomiting episodes did not reach significance (p=0.0552) [3].

What about peppermint oil?

Its evidence base is in irritable bowel syndrome. A meta-analysis of 12 randomized trials with 835 adults found peppermint oil improved global IBS symptoms (risk ratio 2.39, 95% CI 1.93 to 2.97) and abdominal pain (risk ratio 1.78, 95% CI 1.43 to 2.20) compared with placebo [5]. Adverse events were reported by 9.3% on peppermint oil and 6.1% on placebo (risk ratio 1.40, 95% CI 0.87 to 2.26) [5]. Global symptom scores and pain were the primary outcomes; nausea was not among them.

Which label warnings involve stomach symptoms?

Some nausea is expected on Zepbound. The label flags situations where stomach symptoms are part of something more serious:

• Severe GI reactions. Zepbound is not recommended in patients with severe gastroparesis [4].
• Acute kidney injury from volume depletion. The majority of reported events occurred in patients who had nausea, vomiting or diarrhea that led to dehydration, and the label says to monitor renal function in patients with reactions that could cause volume loss, especially during initiation and escalation [4].
• Acute gallbladder disease. Cholecystitis was reported in 0.7% of Zepbound patients versus 0.2% on placebo, cholelithiasis in 1.1% versus 1%, and cholecystectomy in 0.2% versus none [4].
• Acute pancreatitis. This may present as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting; the label says to discontinue Zepbound if pancreatitis is suspected [4].